HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NRXS
NeurAxis, Inc.
There isn't enough reported data to score NRXS yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NRXS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
NRXS's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NRXS PE Valuation
NRXS has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NRXS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect NRXS's losses to shrink, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NRXS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.05 | -$0.03 |
| Q2 2026 | -$0.77 | +$0.26 |
| Q1 2026 | -$0.80 | +$0.43 |
| Q4 2025 | -$0.95 | +$0.27 |
| Q3 2023 | -$2.91 | -$2.22 |
NRXS has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NRXS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over NRXS on profitability, with a higher operating margin.
NRXS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2M | +150% |
| Q2 2026 | $1.9M | +116% |
| Q1 2026 | $1.6M | +80% |
| Q4 2025 | $968.1K | +27% |
| Q3 2025 | $811.4K | +22% |
| Q2 2025 | $894.1K | +46% |
| Q1 2025 | $895.7K | +39% |
| Q4 2024 | $761.2K | +43% |
NRXS's revenue has grown year over year for nine quarters in a row: $2M last quarter, up 150% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -324% | -66 points |
| Q2 2026 | -110% | +82 points |
| Q1 2026 | -108% | +148 points |
| Q4 2025 | -177% | +15 points |
| Q3 2025 | -259% | -11 points |
| Q2 2025 | -192% | +169 points |
| Q1 2025 | -256% | +27 points |
| Q4 2024 | -193% | +113 points |
NRXS's operating margin was −324% last quarter, down 66 points from the same quarter a year ago, near the bottom of its range since 2021.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
NRXS has the stronger cash trend. Its trailing FCF is down 27% versus its history, compared with HIMS at down 84%.
NRXS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.3M | -$840.8K |
| Q4 2025 | -$1.9M | -$181.9K |
| Q3 2025 | -$1.4M | -$30.4K |
| Q2 2025 | -$1.5M | +$149K |
| Q1 2025 | -$1.6M | -$274.8K |
| Q4 2024 | -$1.8M | +$887.4K |
| Q3 2024 | -$1.4M | +$1.4M |
| Q1 2024 | -$1.3M | -$716.4K |
NRXS has burned cash in almost every quarter: −$7M over the past year, against −$6M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NRXS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NRXS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.1% | +865K shares |
| 1 year | +31% | +3.1M shares |
| 3 years | +548% | +11M shares |
NRXS has 13M diluted shares, up 31% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NRXS Net Leverage
NRXS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NRXS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.3 | Neutral |
| Stochastic | 38.7 | Neutral |
NRXS's weekly RSI is 42 (neutral) and its Stochastic is 39 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NRXS PE vs Healthcare Sector
NRXS has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
NRXS has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus NRXS above 1 of 4.
NRXS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.98 | 18% below |
| 20 week MA | $6.73 | 15% below |
| 50 week MA | $6.28 | 8.4% below |
| 100 week MA | $4.39 | 31% above |
NRXS has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 31% above its 100-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
NRXS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $6.15 | $2.67 | -57% |
| 2024 | $2.67 | $2.43 | -9% |
| 2025 | $2.43 | $3.92 | +61% |
| 2026 YTD | $3.92 | $5.75 | +47% |
NRXS has the edge over HIMS on returns for 2026, with the stronger performance.